EMBOLD-GSK
Brief Summary:
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.
Study Title:
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)
Conditions:
Neoplasms, Lung
Pfizer C5751005
Brief Summary:
This is a Phase 3 open-label, randomized, study to evaluate sigvotatug vedotin in combination with pembrolizumab and carboplatin compared to control arm (carboplatin/cisplatin plus pemetrexed and pembrolizumab) as first-line (1L) treatment in participants with locally advanced or metastatic, non-squamous NSCLC without AGAs. The primary objectives of this study are to demonstrate that sigvotatug vedotin in combination with pembrolizumab and carboplatin is superior to carboplatin/cisplatin plus pemetrexed and pembrolizumab in prolonging OS or PFS in the study population.
Study Title:
An Open-Label, Randomized, Controlled, Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab and Carboplatin as First-Line Treatment in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Conditions:
Non-Squamous NSCLC
